Preclinical efficacy of prexasertib in acute lymphoblastic leukemia
Incorporating molecularly targeted therapies into existing chemotherapy regimens holds potential to improve outcomes and reduce both acute and long-term toxicities in acute lymphoblastic leukemia (ALL).
Checkpoint kinase 1 (CHK1), a key regulator of cell cycle arrest in response to DNA damage, is expressed in both T-cell and B-cell ALL, making it a promising therapeutic target.
In this study, we demonstrate that prexasertib, a selective CHK1 inhibitor, exhibits strong single-agent antileukemic activity in vivo in ALL patient-derived xenograft (PDX) models. Additionally, prexasertib shows synergistic effects in vitro when combined with a nucleoside analog.
Conclusion:
These findings support continued clinical investigation of prexasertib as a targeted therapy for ALL.